Get to know our clinical trials
Phase II, open-label, randomized, non-comparative clinical trial of ADP-A2M4CD8 in monotherapy and in combination with nivolumab in patients with recurrent ovarian cancer "Immunotherapy".
THE PURPOSE OF THE TRIAL IS TO LOOK FOR BLOOD BIOMARKERS THAT WILL TELL US WHETHER WE CAN PROPOSE YOU TO PARTICIPATE IN THE MAIN RESEARCH STUDY TO EVALUATE STUDY DRUGS FOR RECURRENT OVARIAN CANCER. NO STUDY DRUGS WILL BE ADMINISTERED DURING PRE-SCREENING.
Cancer Center
Status
In recruitment
headquarters
Pamplona/Madrid
Early phase
Technical Summary
- PHASE II, OPEN-LABEL, RANDOMIZED, NON-COMPARATIVE CLINICAL TRIAL OF ADP-A2M4CD8 IN MONOTHERAPY AND IN COMBINATION WITH NIVOLUMAB IN PATIENTS WITH RECURRENT OVARIAN CANCER "IMMUNOTHERAPY".
- Code EudraCT: 2022-003176-16
- Protocol number: ADP-0055-003
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.